Spatiotemporal‐Controlled NIR‐II Immune Agonist Sensitizes Cancer Immunotherapy
Advanced Materials · 2024
DOI: 10.1002/adma.202400228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Shuai Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Research Institute of Multidisciplinary Science, School of Life Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory…. Hauptthemen laut MEDLINE: Immunotherapy, Nanoparticles, Infrared Rays, Tumor Microenvironment. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Beijing Nova Program.
Abstract (Originalsprache)
The integration of nanomedicine and immunotherapy has presented a promising opportunity for the treatment of cancer and diverse diseases. However, achieving spatiotemporal controllable immunotherapy with excellent efficacy and safety performances remains a significant challenge. This study develops a biodegradable near‐infrared II (NIR‐II) photothermal response polymer nanoparticle (PTEQ) system. This platform exhibits intrinsic immunostimulatory properties while concurrently delivering siRNA for Programmed Death‐Ligand 1 (siPD‐L1), leveraging enhanced immune responses and immune checkpoint blockade for safe and effective cancer therapy. In the CT26 tumor‐bearing mouse model, PTEQ, as an immune stimulant, significantly boosts the infiltration of CD4 + and CD8 + T cells within the tumor microenvironment (TME). The PTEQ/siPD‐L1+laser group not only initiates NIR‐II photothermal therapy but also promotes the activation and infiltration of T cells, M1 macrophage polarization, and maturation of dendritic cells in the TME, resulting in the complete elimination of tumors in 7/10 cases, achieving a 100% survival rate. In another in vivo vaccine experiment, all tumors on the right side are completely eliminated in the PTEQ/siPD‐L1+laser group, reaching a 100% tumor eradication rate. These findings underscore the potential of this strategy to overcome the current immunotherapeutic limitations and achieve immune therapy normalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Research Institute of Multidisciplinary Science, School of Life Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing In…
- Beijing National Laboratory for Molecular Sciences Laboratory of Polymer Physics and Chemistry Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
- School of Dentistry, The University of Queensland, Brisbane, 4006, Australia.
- Department of Nuclear Medicine, Peking University People's Hospital, Beijing, 100044, China.
ORCID-Profile: Yuanyu Huang
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Beijing Nova Program
- Key Technologies Research and Development Program
Zitieren
APA
Guo, S., Tang, D., Zhang, M., Yang, H., Zhang, T., Hu, B., Xu, C., Weng, Y., Shang, K., & Huang, Y. (2024). Spatiotemporal‐Controlled NIR‐II Immune Agonist Sensitizes Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202400228
Vancouver
Guo S, Tang D, Zhang M, Yang H, Zhang T, Hu B, et al. Spatiotemporal‐Controlled NIR‐II Immune Agonist Sensitizes Cancer Immunotherapy. Advanced Materials. 2024. doi:10.1002/adma.202400228
BibTeX
@article{Guo2024,
author = {Guo, Shuai and Tang, Dongsheng and Zhang, Mengjie and Yang, Haiyin and Zhang, Tian and Hu, Bo and Xu, Chun and Weng, Yuhua and Shang, Kun and Huang, Yuanyu},
title = {Spatiotemporal‐Controlled NIR‐II Immune Agonist Sensitizes Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202400228}
}
EUVIMED